查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1372827

口服抗糖尿病藥物市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按藥物、最終用戶按地區和競爭細分

Oral Anti-Diabetic Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drugs, By End Users By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 177 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022年，全球口服抗糖尿病藥物市場估值達到168.9億美元，預計在預測期內將出現大幅成長，預計到2028年年複合成長率（CAGR）為5.47%。口服抗糖尿病藥物市場最近經歷了顯著的成長和轉型，這主要是由於糖尿病盛行率的不斷上升以及藥物研究和開發的不斷進步所推動的。

口服抗糖尿病藥物市場成長的主要驅動力之一是全球糖尿病盛行率的不斷上升。糖尿病的特徵是血糖值長期升高，在全球影響相當多的人。久坐的生活方式、不健康的飲食習慣和人口老化等因素導致糖尿病發生率不斷上升。不斷擴大的患者群體需要多種治療選擇，這凸顯了口服抗糖尿病藥物市場的持續相關性。

口服抗糖尿病藥物市場擁有多樣化的藥物類別組合，每種藥物類別均針對糖尿病管理的不同方面而量身定做。這些藥物類別包括磺醯脲類、雙胍類、胰高血糖素樣勝肽-1 (GLP-1) 受體激動劑、鈉-葡萄糖協同轉運蛋白2 (SGLT2) 抑制劑、二肽基肽酶-4 (DPP-4) 抑制劑等。該市場競爭激烈，老牌製藥公司和新興企業積極爭奪市場佔有率。此次競爭促進了全球口服抗糖尿病藥物市場對產品不斷成長的需求。

市場概況
預測期 2024-2028
2022 年市場規模 168.9億美元
2028 年市場規模 231.9億美元
2023-2028 年年複合成長率 5.47%
成長最快的細分市場 醫院
最大的市場 北美洲

主要市場促進因素

全球糖尿病盛行率不斷上升

口服抗糖尿病藥物的主要和最有影響力的市場促進因素之一是全球糖尿病盛行率的不斷上升。根據國際糖尿病聯盟的數據，2021 年約有5.37 億人患有糖尿病，預計到2030 年這一數字將增至6.43 億。久坐的生活方式、不良飲食選擇和人口老化等因素加劇了糖尿病病例的驚人成長。隨著糖尿病患者數量持續激增，對有效治療方案的需求也增加，使得口服抗糖尿病藥物市場不可或缺。以伏案工作、長時間看螢幕和減少體力活動為特徵的現代生活方式導致肥胖風險增加，進而導致第 2 型糖尿病風險增加。

藥物配方的進步

藥物配方的進步是口服抗糖尿病藥物市場的另一個重要驅動力。製藥公司不斷投資研發，為糖尿病患者創造更安全、更有效、更方便的藥物。固定劑量聯合療法代表了口服抗糖尿病藥物製劑的另一個重大進步。這些療法將多種藥物組合到一個藥片中，簡化了治療方案並提高了患者的依從性。透過同時針對糖尿病病理生理學的多個方面，固定劑量組合可增強血糖控制並降低低血糖風險。患者不再需要同時服用多種藥物或記住複雜的給藥方案，這使他們更容易有效地管理糖尿病。現有口服抗糖尿病藥物的長效製劑也促進了市場的成長。二甲雙胍是一種廣泛使用的雙胍類藥物，幾十年來一直是糖尿病治療的基石。二甲雙胍的緩釋版本允許每日一次給藥，為患者提供持續的血糖控制和更大的便利性。這項創新不僅提高了藥物依從性，而且還降低了與速釋製劑相關的副作用的可能性。

此外，遺傳學和生物標記研究的進步為糖尿病領域更個人化的醫療方法鋪平了道路。這使得醫療保健提供者能夠根據個別患者的獨特需求量身定做治療計劃，最佳化口服抗糖尿病藥物的有效性。透過識別影響患者對藥物反應的特定遺傳標記或生物標記，可以選擇最合適的藥物和劑量，從而獲得更好的結果和更少的副作用。

提高認知和診斷

對糖尿病及其管理的認知不斷提高是口服抗糖尿病藥物市場的重要驅動力。醫療保健活動、患者教育措施以及醫療專業人員的努力促進了糖尿病診斷率的提高。早期診斷有助於及時干涉，並且更有可能使用口服抗糖尿病藥物。此外，意識到與不受控制的糖尿病相關的潛在併發症的患者更有可能遵守他們規定的藥物治療方案。

早期診斷的好處是多方面的。首先，它使個人能夠了解自己的病情，使他們能夠採取積極措施來管理糖尿病。其次，它允許醫療保健提供者儘早開始治療，最大限度地降低併發症的風險並最佳化血糖控制。第三，它為及時、知情地討論治療方案（包括使用口服抗糖尿病藥物）打開了大門。隨著認知和診斷的提高，對口服抗糖尿病藥物的需求激增。這些藥物已成為糖尿病管理計畫不可或缺的一部分，特別是對於第 2 型糖尿病患者。不同類別的口服抗糖尿病藥物，如磺醯脲類、雙胍類、二肽基肽酶4 (DPP-4) 抑制劑和鈉-葡萄糖協同轉運蛋白2 (SGLT2) 抑制劑，為個別患者提供了一系列量身訂製的治療選擇需要。此外，早期診斷對患者遵守處方藥物治療方案產生了深遠的影響。了解自己的病情及其潛在後果的患者更有可能按照指示服用藥物。這種堅持對於實現和維持最佳血糖控制至關重要，這對於預防糖尿病相關併發症至關重要。

不斷擴大的老年人口

人口老化是口服抗糖尿病藥物市場的關鍵人口促進因素。由於與年齡相關的生理變化，老年人更容易患第 2 型糖尿病，這使他們成為這些藥物的重要消費群體。隨著全球人口持續老化，口服抗糖尿病藥物市場預計將進一步擴大。全球人口老化是一場具有深遠意義的人口變化。醫療保健和生活條件的改善延長了預期壽命，導致老年人口數量不斷增加。由於與年齡相關的生理變化，老年人罹患第 2 型糖尿病的風險更高。胰島素敏感性降低、葡萄糖耐受受損和胰腺功能改變等因素使老年人更容易患這種代謝紊亂。隨著老年人口的增加，該年齡層糖尿病的盛行率也增加。根據國際糖尿病聯盟 (IDF) 的數據，65 歲及以上的人群中很大一部分患有糖尿病。老年人糖尿病病例的激增對口服抗糖尿病藥物市場產生了直接影響。

口服抗糖尿病藥物對於控制老年人糖尿病至關重要。這些藥物提供了一種方便有效的控制血糖水平的方法，這是糖尿病管理的一個重要方面，特別是在老年人群中。它們透過多種機制發揮作用，包括刺激胰島素分泌、提高胰島素敏感性和減少肝臟中葡萄糖的產生，使其成為血糖控制的多功能工具。此外，不斷成長的老年人口促使醫療保健系統和提供者採用更全面的糖尿病管理方法。

主要市場挑戰

高昂的醫療費用

糖尿病管理與大量醫療費用有關，包括藥物、監測設備和頻繁的醫療諮詢。這些成本可能會給醫療保健系統、保險公司和患者帶來巨大的經濟負擔。口服抗糖尿病藥物的可負擔性和可及性是關鍵問題，特別是在低收入和中等收入國家，許多人可能難以獲得和負擔必要的藥物。有效糖尿病管理道路上最突出的障礙之一是它給個人和醫療保健提供者帶來的經濟負擔。糖尿病照護涵蓋一系列費用，包括口服抗糖尿病藥物的價格、監測設備、定期體檢以及因糖尿病相關併發症而可能住院的費用。這些費用會迅速累積並導致患者及其家人的經濟資源緊張。

口服抗糖尿病藥物對於控制血糖水平至關重要，其成本是糖尿病相關醫療費用的重要組成部分。雖然這些藥物對許多患者來說是必不可少的，但它們的價格可能令人望而卻步，特別是對於那些沒有足夠保險的患者來說。

副作用和安全問題

許多口服抗糖尿病藥物都有潛在的副作用，並非所有患者都能很好地耐受這些藥物。例如，某些磺醯脲類藥物可能導致低血糖，某些藥物可能與體重增加有關。對於患者和醫療保健提供者來說，平衡這些藥物的益處與潛在的副作用可能都是一項挑戰。

與口服抗糖尿病藥物相關的主要問題之一是低血糖的風險，低血糖是一種以危險的低血糖水平為特徵的疾病。這些藥物中的某些類別（例如磺醯脲類）會刺激胰臟釋放更多胰島素。雖然這有助於降低血糖水平，但有時會導致胰島素分泌過多，進而導致低血糖。嚴重的低血糖可能會危及生命，而對這種副作用的恐懼可能會阻止患者堅持用藥方案。另一個擔憂是一些口服抗糖尿病藥物可能導致體重增加，特別是磺醯脲類和噻唑烷二酮類藥物。體重增加會加劇其他健康問題，例如肥胖和心血管疾病，這是糖尿病患者常見的合併症。對體重增加的恐懼可能會導致患者避免或停止用藥，進而影響血糖控制。

服藥依從性

藥物依從性仍然是糖尿病管理中普遍存在的挑戰。患者經常被開出複雜的藥物治療方案，其中涉及多種口服抗糖尿病藥物，並且嚴格遵守這些治療方案可能很困難。不依從可能導致血糖控制不佳、併發症風險增加、醫療費用更高。不依從的主要原因之一是藥物治療方案的複雜性。許多醣尿病患者會服用多種藥物，每種藥物都有自己的給藥方案。管理這種複雜性可能會令人難以承受，從而導致混亂和錯過劑量。此外，對低血糖或體重增加等潛在副作用的恐懼可能會阻礙患者按處方服用藥物。

患者也可能因認為藥物無效或症狀無法立即緩解而停止用藥。與某些在開始治療後不久症狀改善明顯的醫療狀況不同，糖尿病治療通常需要持續、長期的藥物治療以預防併發症，這使得患者很難認知到堅持治療的好處。

主要市場趨勢

個人化醫療方法

個體化用藥已成為口服抗糖尿病藥物市場的重要趨勢。認知到糖尿病是一種高度異質性的疾病，醫療保健提供者擴大根據患者的個別需求制定治療計劃。基因檢測和生物標記研究使藥物選擇和劑量更加精確，最佳化治療結果並最大限度地減少副作用。糖尿病管理中「一刀切」的概念正逐漸讓位給考慮遺傳因素、合併症和患者偏好的客製化療法。這一趨勢正在提高口服抗糖尿病藥物的有效性和安全性。

監理支援和快速核准

世界各地的監管機構已承諾透過簡化口服抗糖尿病藥物的核准流程來解決糖尿病流行問題。糖尿病挑戰的迫切性促使監管機構提供加速藥物核准的途徑，使創新藥物更快進入市場。這種監管支持鼓勵製藥公司投資於糖尿病研究和開發，從而產生了一系列有前景的口服抗糖尿病藥物。新藥更快地推向市場對患者和醫療保健系統都有好處。

藥物配方的創新

口服抗糖尿病藥物市場最突出的趨勢之一是藥物配方的不斷進步。製藥公司正在投資研發，以創造更有效、更安全、對病人友善的藥物。口服胰高血糖素樣勝肽 1 (GLP-1) 受體激動劑、固定劑量聯合療法和緩釋製劑等創新擴大了治療選擇並提高了患者的依從性。例如，口服 GLP-1 受體激動劑已成為一項突破性的發展，以更方便的片劑形式提供了 GLP-1 治療的益處。這增加了以前不願意使用注射 GLP-1 激動劑的患者的可及性和接受度。

細分市場洞察

藥物見解

基於這些藥物，雙胍類藥物細分市場將在 2022 年成為全球口服抗糖尿病藥物市場的主導者。這是由於雙胍類藥物在糖尿病管理中的功效和廣泛使用。雙胍類藥物長期以來一直是治療第2型糖尿病的基石，其中二甲雙胍是最知名的代表。二甲雙胍是最常用的雙胍類藥物，具有有效降低血糖水平的良好記錄。它的主要作用是減少肝臟的葡萄糖產生並增強週邊組織的胰島素敏感性。其功效和安全性使其成為第 2 型糖尿病的一線治療方法。二甲雙胍的學名藥已廣泛使用，使其成為患者和醫療保健系統具有成本效益的選擇。此外，二甲雙胍經常與其他口服抗糖尿病藥物合併使用，增強其治療計畫的多功能性。包括二甲雙胍在內的固定劑量合併療法很容易取得，可以簡化用藥方案並提高患者的依從性。

雙胍類藥物（尤其是二甲雙胍）在 2022 年全球口服抗糖尿病藥物市場中的主導地位反映了其公認的功效、安全性、心血管益處、體重中性或減肥效果以及成本效益。由於糖尿病仍然是全球普遍存在的健康問題，雙胍類藥物預計將保持其在糖尿病管理策略中的突出地位，為患有這種慢性病的患者帶來希望並改善結果。

區域洞察

2022年，北美成為全球口服抗糖尿病藥物市場的主導者，佔最大的市場。這是因為先進的醫療基礎設施、糖尿病的高盛行率和強勁的製藥業。北美是一些世界上最大的製藥公司的所在地，這些公司專注於糖尿病的研究和開發。這些公司大力投資開發創新的口服抗糖尿病藥物，這些藥物可供該地區的患者使用。北美的監管機構，例如美國食品藥物管理局 (FDA) 和加拿大衛生部，維持嚴格的藥物核准標準。嚴格的監管環境確保只有安全有效的藥物才能進入市場，從而增強醫療保健提供者和患者的信心。

由於人口迅速成長、糖尿病盛行率不斷上升以及糖尿病管理意識不斷增強，亞太地區預計在未來幾年將佔據最大佔有率。隨著生活方式的改變和城市化的持續，預計亞太地區對口服抗糖尿病藥物的需求將不斷成長，使其成為全球市場格局的關鍵參與者。

目錄

第 1 章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場區隔

第 2 章：研究方法

  • 研究目的
  • 基線方法
  • 主要產業夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 數據三角測量與驗證
  • 假設和限制

第 3 章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依藥物（雙胍類、α-葡萄糖苷酶抑制劑、多巴胺-D2 受體激動劑、鈉-葡萄糖共轉運-2 (SGLT-2) 抑制劑、二肽基肽酶- 4 (DPP-4) 抑制劑、磺脲類、美格列奈類）
    • 最終使用者（醫院、家庭護理、專科中心、其他）
    • 按公司分類 (2022)
    • 按地區
  • 市場地圖

第 6 章：北美口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物分類
    • 由最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 7 章：歐洲口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物分類
    • 由最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物分類
    • 由最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物分類
    • 由最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第10章 ：中東和非洲口服抗糖尿病藥物市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按藥物分類
    • 由最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非口服抗糖尿病藥
    • 沙烏地阿拉伯口服抗糖尿病藥
    • 阿拉伯聯合大公國口服抗糖尿病藥物

第 11 章：市場動態

  • 促進要素
  • 挑戰

第 12 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代藥物的威脅

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（上市公司）
  • 最近的發展
  • SWOT分析
    • KONINKLIJKE PHILIPS NV
    • Sanofi SA
    • Eli Lilly and Company
    • AstraZeneca
    • Astellas Pharma Inc.
    • Johnson & Johnson (Janssen Pharmaceuticals)
    • Boehringer Ingelheim
    • Merck And Co.
    • Bristol Myers Squibb Company
    • Novartis AG

第 16 章：策略建議

簡介目錄
Product Code: 16137

In 2022, the Global Oral Anti-Diabetic Drugs Market reached a valuation of USD 16.89 billion, and it is poised to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.47% through 2028. The global Oral Anti-Diabetic Drugs market has undergone significant growth and transformation recently, primarily driven by the increasing prevalence of diabetes and ongoing advancements in pharmaceutical research and development.

One of the primary drivers of the Oral Anti-Diabetic Drugs market's growth is the escalating worldwide prevalence of diabetes. Diabetes, characterized by chronically elevated blood glucose levels, affects a considerable number of people on a global scale. Factors such as sedentary lifestyles, unhealthy dietary habits, and an aging population contribute to the growing incidence of diabetes. This expanding patient population necessitates a wide array of treatment options, underscoring the continued relevance of the Oral Anti-Diabetic Drugs market.

The Oral Anti-Diabetic Drugs market boasts a diverse portfolio of drug classes, each tailored to address different facets of diabetes management. These drug classes include Sulfonylureas, Biguanides, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, and others. This market is marked by robust competition, with established pharmaceutical companies and emerging players actively competing for market share. This competition contributes to the growing demand for products within the Global Oral Anti-Diabetic Drugs Market.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 16.89 Billion
Market Size 2028USD 23.19 Billion
CAGR 2023-20285.47%
Fastest Growing SegmentHospitals
Largest MarketNorth America

Key Market Drivers

Increasing Global Diabetes Prevalence

One of the primary and most influential market drivers for Oral Anti-Diabetic Drugs is the escalating prevalence of diabetes on a global scale. According to the International Diabetes Federation, approximately 537 million people had diabetes in 2021, a number projected to rise to 643 million by 2030. This alarming increase in diabetes cases is fueled by factors such as sedentary lifestyles, poor dietary choices, and the aging population. As the number of individuals living with diabetes continues to surge, so does the demand for effective treatment options, making the Oral Anti-Diabetic Drugs market indispensable. Modern lifestyles characterized by desk-bound jobs, prolonged screen time, and reduced physical activity have contributed to an increased risk of obesity and, subsequently, type 2 diabetes.

The escalating prevalence of diabetes serves as a wake-up call, demanding innovative solutions to curb its impact and provide effective treatment options to those affected. Oral anti-diabetic drugs are positioned at the forefront of this battle against diabetes. These medications offer a versatile approach to managing disease, catering to the diverse needs of diabetic patients. Pharmaceutical companies, recognizing the urgency of the diabetes epidemic, have accelerated their research and development efforts in response. Advancements in drug formulations have been a pivotal driving force behind the market's growth. Traditionally, injectable glucagon-like peptide-1 (GLP-1) receptor agonists have been pivotal in diabetes management. However, the introduction of oral GLP-1 receptor agonists has marked a significant breakthrough. These oral tablets mimic the effects of GLP-1, promoting insulin secretion and weight loss, and have expanded accessibility and acceptance among patients.

Advancements in Drug Formulations

Advancements in drug formulations represent another significant driver of the Oral Anti-Diabetic Drugs market. Pharmaceutical companies are continually investing in research and development to create safer, more effective, and more convenient medications for diabetic patients. Fixed-dose combination therapies represent another significant advancement in oral anti-diabetic drug formulations. These therapies combine multiple medications into a single tablet, simplifying treatment regimens and improving patient compliance. By targeting multiple aspects of diabetes pathophysiology simultaneously, fixed-dose combinations enhance glycemic control and reduce the risk of hypoglycemia. Patients no longer need to juggle multiple pills or remember complex dosing schedules, making it easier for them to manage their diabetes effectively. Long-acting formulations of existing oral anti-diabetic drugs have also contributed to the market's growth. Metformin, a widely prescribed biguanide, has been a cornerstone in diabetes management for decades. Extended-release versions of metformin allow for once-daily dosing, providing sustained blood sugar control and greater convenience for patients. This innovation has not only improved medication adherence but has also reduced the likelihood of side effects associated with immediate-release formulations.

Moreover, advancements in genetics and biomarker research have paved the way for more personalized medicine approaches in the field of diabetes. This allows healthcare providers to tailor treatment plans to individual patients' unique needs, optimizing the effectiveness of oral anti-diabetic drugs. By identifying specific genetic markers or biomarkers that influence a patient's response to medication, it is possible to select the most suitable drug and dosage, leading to better outcomes and fewer side effects.

Increasing Awareness and Diagnosis

Growing awareness about diabetes and its management is a vital driver for the Oral Anti-Diabetic Drugs market. Healthcare campaigns, patient education initiatives, and the efforts of medical professionals have contributed to higher rates of diabetes diagnosis. Early diagnosis leads to timely interventions and a greater likelihood of oral anti-diabetic drug use. Moreover, patients who are aware of the potential complications associated with uncontrolled diabetes are more likely to adhere to their prescribed medication regimens.

The benefits of early diagnosis are manifold. Firstly, it empowers individuals with the knowledge of their condition, enabling them to take proactive measures to manage their diabetes. Secondly, it allows healthcare providers to initiate treatment early, minimizing the risk of complications and optimizing glycemic control. Thirdly, it opens the door to timely and informed discussions about treatment options, including the use of oral anti-diabetic drugs. With increased awareness and diagnosis, the demand for oral anti-diabetic drugs has surged. These medications have become integral components of diabetes management plans, particularly for individuals with type 2 diabetes. The diverse classes of oral anti-diabetic drugs, such as sulfonylureas, biguanides, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-glucose co-transporter 2 (SGLT2) inhibitors, offer a range of treatment options tailored to individual patient needs. Moreover, early diagnosis has had a profound impact on patient adherence to prescribed medication regimens. Patients who are aware of their condition and its potential consequences are more likely to take their medications as directed. This adherence is crucial for achieving and maintaining optimal glycemic control, which is essential in preventing diabetes-related complications.

Expanding Geriatric Population

The aging population is a key demographic driver of the Oral Anti-Diabetic Drugs market. Older adults are more susceptible to developing type 2 diabetes due to age-related physiological changes, making them a significant consumer segment for these medications. As the global population continues to age, the market for oral anti-diabetic drugs is expected to expand further. The aging of the global population is a demographic shift of profound significance. Improved healthcare and living conditions have resulted in longer life expectancy, leading to an increasingly larger segment of elderly individuals. Older adults are at a heightened risk of developing type 2 diabetes due to age-related physiological changes. Factors such as decreased insulin sensitivity, impaired glucose tolerance, and alterations in pancreatic function make aging adults more susceptible to this metabolic disorder. As the geriatric population expands, so does the prevalence of diabetes in this age group. According to the International Diabetes Federation (IDF), a significant proportion of people aged 65 and older are living with diabetes. This surge in diabetes cases among older adults has a direct impact on the Oral Anti-Diabetic Drugs market.

Oral anti-diabetic drugs have become essential in managing diabetes among older adults. These medications offer a convenient and effective means of controlling blood glucose levels, a critical aspect of diabetes management, especially in the elderly population. They work by various mechanisms, including stimulating insulin secretion, improving insulin sensitivity, and reducing glucose production in the liver, making them versatile tools in glycemic control. Additionally, the growing geriatric population has prompted healthcare systems and providers to adopt a more comprehensive approach to diabetes management.

Key Market Challenges

High Healthcare Costs

Diabetes management is associated with substantial healthcare costs, including medications, monitoring devices, and frequent medical consultations. These costs can place a significant financial burden on healthcare systems, insurers, and patients. Affordability and accessibility to oral anti-diabetic drugs are critical issues, particularly in low- and middle-income countries, where many individuals may struggle to access and afford necessary medications. One of the most prominent hurdles in the path of effective diabetes management is the financial burden it places on individuals and healthcare providers. Diabetes care encompasses a range of costs, including the price of oral anti-diabetic drugs, monitoring devices, regular medical check-ups, and potential hospitalization for diabetes-related complications. These expenses can accumulate rapidly and strain the financial resources of patients and their families.

The cost of oral anti-diabetic drugs, which are fundamental to controlling blood sugar levels, is a substantial component of diabetes-related healthcare expenses. While these medications are indispensable for many patients, their prices can be prohibitive, especially for those without adequate insurance coverage.

Side Effects and Safety Concerns

Many oral anti-diabetic drugs come with potential side effects, and not all patients tolerate these medications well. For instance, some sulfonylureas can cause hypoglycemia, and certain medications may be associated with weight gain. Balancing the benefits of these drugs with potential adverse effects can be challenging for both patients and healthcare providers.

One of the primary concerns associated with oral anti-diabetic drugs is the risk of hypoglycemia, a condition characterized by dangerously low blood sugar levels. Certain classes of these drugs, such as sulfonylureas, stimulate the pancreas to release more insulin. While this helps lower blood sugar levels, it can sometimes lead to excessive insulin production and subsequent hypoglycemia. Severe hypoglycemia can be life-threatening, and the fear of this side effect can deter patients from adhering to their medication regimens. Another concern is the potential for weight gain associated with some oral anti-diabetic drugs, particularly sulfonylureas and thiazolidinediones. Weight gain can exacerbate other health issues, such as obesity and cardiovascular disease, which are common comorbidities in individuals with diabetes. The fear of weight gain may lead patients to avoid or discontinue medications, compromising their glycemic control.

Medication Adherence

Medication adherence remains a pervasive challenge in diabetes management. Patients are often prescribed complex medication regimens that involve multiple oral anti-diabetic drugs, and maintaining strict adherence to these regimens can be difficult. Non-adherence can lead to poor glycemic control, increased risk of complications, and higher healthcare costs. One of the primary reasons for non-adherence is the complexity of medication regimens. Many individuals with diabetes are prescribed multiple medications, each with its own dosing schedule. Managing this complexity can be overwhelming, leading to confusion and missed doses. Moreover, the fear of potential side effects, such as hypoglycemia or weight gain, can discourage patients from taking their medications as prescribed.

Patients may also discontinue their medications due to perceived ineffectiveness or a lack of immediate symptomatic relief. Unlike some medical conditions where symptom improvement is noticeable shortly after starting treatment, diabetes management often requires consistent, long-term medication use to prevent complications, making it challenging for patients to recognize the benefits of adherence.

Key Market Trends

Personalized Medicine Approaches

Personalized medicine has become a significant trend in the Oral Anti-Diabetic Drugs market. Recognizing that diabetes is a highly heterogeneous condition, healthcare providers are increasingly tailoring treatment plans to individual patient needs. Genetic testing and biomarker research have enabled more precise drug selection and dosing, optimized treatment outcomes and minimizing side effects. The concept of "one size fits all" in diabetes management is gradually giving way to tailored therapies that consider genetic factors, comorbidities, and patient preferences. This trend is enhancing the effectiveness and safety of oral anti-diabetic drugs.

Regulatory Support and Expedited Approvals

Regulatory bodies worldwide have shown a commitment to addressing the diabetes epidemic by streamlining the approval process for oral anti-diabetic drugs. The urgency of the diabetes challenge has prompted regulatory agencies to provide accelerated pathways for drug approval, allowing innovative medications to reach the market more quickly. This regulatory support has encouraged pharmaceutical companies to invest in diabetes research and development, resulting in a pipeline of promising oral anti-diabetic drugs. The faster introduction of new medications to the market benefits patients and healthcare systems alike.

Innovations in Drug Formulations

One of the most prominent trends in the Oral Anti-Diabetic Drugs market is the continuous advancement of drug formulations. Pharmaceutical companies are investing in research and development to create more effective, safer, and patient-friendly medications. Innovations such as oral Glucagon-Like Peptide-1 (GLP-1) receptor agonists, fixed-dose combination therapies, and extended-release formulations have expanded treatment options and improved patient adherence. Oral GLP-1 receptor agonists, for instance, have emerged as a groundbreaking development, offering the benefits of GLP-1 therapy in a more convenient tablet form. This has increased accessibility and acceptance among patients who may have previously been reluctant to use injectable GLP-1 agonists.

Segmental Insights

Drugs Insights

Based on the drugs, the Biguanides segment emerged as the dominant player in the global market for Oral Anti-Diabetic Drugs Market in 2022. This is on account of the efficacy and widespread use of Biguanides in diabetes management. Biguanides, with metformin being the most well-known representative, have long been a cornerstone in the treatment of type 2 diabetes. Metformin, the most prescribed Biguanide, has a proven track record of effectively lowering blood glucose levels. It primarily works by reducing the liver's glucose production and enhancing insulin sensitivity in peripheral tissues. Its efficacy and safety profile have made it a first-line treatment for type 2 diabetes. Generic versions of metformin are widely available, making it a cost-effective option for both patients and healthcare systems. Moreover, Metformin is often used in combination with other oral anti-diabetic drugs, enhancing its versatility in treatment plans. Fixed-dose combination therapies that include metformin are readily available, simplifying medication regimens and improving patient adherence.

The dominance of the Biguanides segment, particularly metformin, in the global Oral Anti-Diabetic Drugs market in 2022 is a reflection of its well-established efficacy, safety profile, cardiovascular benefits, weight-neutral or weight-loss effects, and cost-effectiveness. As diabetes continues to be a prevalent global health concern, Biguanides are expected to maintain their prominent position in diabetes management strategies, offering hope and improved outcomes for individuals living with this chronic condition.

Regional Insights

North America emerged as the dominant player in the global Oral Anti-Diabetic Drugs Market in 2022, holding the largest market share. This is on account of advanced healthcare infrastructure, high prevalence of diabetes, and a robust pharmaceutical industry. North America is home to some of the world's largest pharmaceutical companies with a strong focus on diabetes research and development. These companies invest heavily in developing innovative oral anti-diabetic drugs, which are readily available to patients in the region. Regulatory agencies in North America, such as the U.S. Food and Drug Administration (FDA) and Health Canada, maintain rigorous standards for drug approval. The stringent regulatory environment ensures that only safe and effective medications enter the market, instilling confidence in healthcare providers and patients.

Asia-Pacific is anticipated to hold the largest share in the coming years, on account of its rapidly expanding population, increasing prevalence of diabetes, and growing awareness of diabetes management. As lifestyles change and urbanization continues, the Asia-Pacific region is expected to experience a growing demand for oral anti-diabetic drugs, making it a pivotal player in the global market landscape.

Key Market Players

  • KONINKLIJKE PHILIPS N.V.
  • Sanofi S.A.
  • Eli Lilly and Company
  • AstraZeneca
  • Astellas Pharma Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals)
  • Boehringer Ingelheim
  • Merck And Co.
  • Bristol Myers Squibb Company
  • Novartis AG

Report Scope:

In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Anti-Diabetic Drugs Market, By Drugs:

  • Biguanides
  • Alpha-glucosidase inhibitors
  • Dopamine -D2 Receptor Agonist
  • Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
  • Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
  • Sulfonylureas
  • Meglitinides

Oral Anti-Diabetic Drugs Market, By End Users:

  • Hospitals
  • Homecare
  • Speciality Centers
  • Others

Oral Anti-Diabetic Drugs Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market.

Available Customizations:

  • Global Oral Anti-Diabetic Drugs Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Anti-Diabetic Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides)
    • 5.2.2. End Users (Hospitals, Homecare, Speciality Centres, Others)
    • 5.2.3. By Company (2022)
    • 5.2.4. By Region
  • 5.3. Market Map

6. North America Oral Anti-Diabetic Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By End Users
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By End Users
    • 6.3.2. Mexico Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By End Users
    • 6.3.3. Canada Oral Anti-Diabetic Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By End Users

7. Europe Oral Anti-Diabetic Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By End Users
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By End-users
    • 7.3.2. Germany Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By End-users
    • 7.3.3. United Kingdom Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By End-users
    • 7.3.4. Italy Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By End-users
    • 7.3.5. Spain Oral Anti-Diabetic Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By End-users

8. Asia-Pacific Oral Anti-Diabetic Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By End-users
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By End-users
    • 8.3.2. India Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By End-users
    • 8.3.3. South Korea Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By End-users
    • 8.3.4. Japan Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drugs
        • 8.3.4.2.2. By End-users
    • 8.3.5. Australia Oral Anti-Diabetic Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drugs
        • 8.3.5.2.2. By End-users

9. South America Oral Anti-Diabetic Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By End-users
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By End-users
    • 9.3.2. Argentina Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By End-users
    • 9.3.3. Colombia Oral Anti-Diabetic Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By End-users

10. Middle East and Africa Oral Anti-Diabetic Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By End-users
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By End-users
    • 10.3.2. Saudi Arabia Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By End-users
    • 10.3.3. UAE Oral Anti-Diabetic Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By End-users

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Drugs

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (In case of listed companies)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. KONINKLIJKE PHILIPS N.V.
    • 15.6.2. Sanofi S.A.
    • 15.6.3. Eli Lilly and Company
    • 15.6.4. AstraZeneca
    • 15.6.5. Astellas Pharma Inc.
    • 15.6.6. Johnson & Johnson (Janssen Pharmaceuticals)
    • 15.6.7. Boehringer Ingelheim
    • 15.6.8. Merck And Co.
    • 15.6.9. Bristol Myers Squibb Company
    • 15.6.10. Novartis AG

16. Strategic Recommendations